Follow The Filings

MANE Veradermics Inc.

Health Care, filed as VERADERMICS INC (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 3 Owners
  • Max 0.9%
  • $317M
  • 1 new 1 add 1 reduce

In 2026 Q2 Lee Ainslie opened a position in Veradermics, Ron Baron added, and Andreas Halvorsen trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.9% (Lee Ainslie, Maverick Capital). Not free-float ownership.

  1. Lee Ainslie New 0.86%
  2. Andreas Halvorsen Reduce 0.55%
  3. Ron Baron Add 0.04%

Who owns MANE

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.55% Reduce −7.6% 1,561,494 $192M History
Lee Ainslie, Maverick Capital 0.86% New 0.86% 789,980 $97M History
Ron Baron, Bamco Inc. (Baron Capital) 0.04%, was 0.01% Add +284.8% 229,581 $28M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MANE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MANE insider trades
  • $54.1M bought by 5 insiders
  • $91.1M sold by 2 insiders outside a trading plan
  • $12M sold by 2 insiders under 10b5-1 plans
  1. Montanova Capital, LLC Director, +3 joint filers
    Sale
    $80.4M 750,000 shares at $107.25 62% of stake
    Traded Aug 19 Filed Aug 21
  2. Timothy August Durso Chief Technical Officer
    Planned sale
    $4.7M 43,500 shares at $107.82 36% of stake
    Traded Aug 17 Filed Aug 18
  3. Reid Alexander Waldman CEO
    Planned sale
    $7.3M 67,500 shares at $107.86 28% of stake
    Traded Aug 17 Filed Aug 18
  4. John W Childs Director
    Sale
    $10.7M 100,000 shares at $107.12 34% of stake
    Traded Aug 12 Filed Aug 14
  5. John W Childs Director
    Buy
    $5M 294,117 shares at $17.00 New stake
    Traded Feb 5 Filed Feb 27
  6. Suvretta Capital Management, LLC Director, +3 joint filers
    Buy
    $10.5M 282,674 shares at $37.30 +119% to stake
    Traded Feb 4–6 Filed Feb 9
  7. Vlad Coric Director
    Buy
    $2M 117,646 shares at $17.00 +58% to stake
    Traded Feb 5 Filed Feb 5
  8. Longitude Capital Partners V, LLC 10% owner, +3 joint filers
    Buy
    $18.3M 1,075,000 shares at $17.00 +110% to stake
    Traded Feb 5 Filed Feb 5

Also filed in the last 12 months, not counted as buying or selling: 19 conversions, 4 option exercises, and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01
SCHEDULE 13G —
SCHEDULE 13D/A —
SCHEDULE 13D/A —
424B3
8-K 2.02,9.01
10-Q
S-1
SCHEDULE 13G —
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13D —
SCHEDULE 13D/A —
SCHEDULE 13D/A —
8-K 1.01,3.02,9.01
424B4 424B3
8-K 7.01,8.01,9.01
8-K 2.02
S-1
8-K 2.02,9.01
10-K
SCHEDULE 13G —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2025
Net income -$70M

Balance sheet

Metric FY2025
Total current assets $152.49M
Total non-current assets $125,000
Total assets $152.62M
Total current liabilities $9.15M
Total non-current liabilities * $4,000
Total equity -$121.01M

Cash flow

Metric FY2025
Cash from operations -$71.6M
Cash from investing -$118.86M
Cash from financing $159.14M
Net change in cash -$31.32M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.